Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Argenx SE    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report
Delayed Quote. Delayed Euronext Bruxelles - 02/21 11:35:13 am
150.4 EUR   +0.60%
02/20ARGENX : to report full year 2019 financial results and fourth quarter business update on February 27, 2020
PU
01/20ARGENX SE : Crossing thresholds
CO
01/17ARGENX SE : Crossing thresholds
CO
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
148.6(c) 147.8(c) 151.8(c) 149.5(c) 150.4(c) Last
33 671 49 334 72 156 94 264 70 901 Volume
-0.47% -0.54% +2.71% -1.52% +0.60% Change
More quotes
Financials (EUR)
Sales 2019 80,2 M
EBIT 2019 -143 M
Net income 2019 -106 M
Finance 2019 918 M
Yield 2019 -
Sales 2020 65,5 M
EBIT 2020 -241 M
Net income 2020 -237 M
Finance 2020 719 M
Yield 2020 -
P/E ratio 2019 -57,1x
P/E ratio 2020 -21,0x
EV / Sales2019 68,7x
EV / Sales2020 87,3x
Capitalization 6 431 M
More Financials
Company
argenx SE is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group is focused on developing product candidates with the potential to be either first-in-class against novel... 
More about the company
Surperformance© ratings of argenx SE
Trading Rating : Investor Rating :
More Ratings
Latest news on ARGENX SE
02/20ARGENX : to report full year 2019 financial results and fourth quarter business ..
PU
01/20ARGENX SE : Crossing thresholds
CO
01/17ARGENX SE : Crossing thresholds
CO
01/15ARGENX SE : Crossing thresholds
CO
01/14ARGENX SE : Crossing thresholds
CO
01/09Europe stocks resume record run as Middle East tensions ease
RE
01/09ARGENX : Provides Strategic Outlook Advancing Late-Stage Pipeline Towards 'argen..
AQ
01/09ARGENX : Provides Strategic Outlook Advancing Late-Stage Pipeline Towards &lsquo..
PU
01/09ARGENX SE : Crossing thresholds
CO
01/07ARGENX SE : Crossing thresholds
CO
2019ARGENX SE : Admission of new securities
CO
2019ARGENX SE : Crossing thresholds
CO
2019ARGENX SE : Crossing thresholds
CO
2019ARGENX SE : Crossing thresholds
CO
2019ARGENX SE : Crossing thresholds
CO
More news
News in other languages on ARGENX SE
02/21BB Biotech prévoit un potentiel de croissance intact en 2020
01/31EVOTEC : Sorgt diese Erfolgsmeldung für die nächste Kurs-Rallye?
01/29AVIS D'ANALYSTES DU JOUR : Airbus, LVMH, Ubisoft, bioMérieux, ArgenX, Moncler, S..
01/29STOCK MARKET PARIS : Les marchés replongent dans les résultats d'entreprises
01/20DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 20.01.2020 - 15.15 Uhr
More news
Analyst Recommendations on ARGENX SE
More recommendations
Sector news : Bio Therapeutic Drugs
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Bio Therapeutic Drugs
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | ARGX | NL0010832176 | MarketScreener
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 147,25  €
Last Close Price 150,40  €
Spread / Highest target 6,38%
Spread / Average Target -2,09%
Spread / Lowest Target -10,2%
EPS Revisions
Managers
NameTitle
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Peter K. M. Verhaeghe Chairman
R. Keith Woods Chief Operating Officer
Eric Castaldi CFO & Principal Accounting Officer
Hans J. W. de Haard Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARGENX SE4.74%6 986
GILEAD SCIENCES3.11%84 765
VERTEX PHARMACEUTICALS12.49%63 547
REGENERON PHARMACEUTICALS6.30%43 450
WUXI APPTEC CO., LTD.20.50%25 998
GENMAB14.61%15 962